Detail akcie Lexicon Pharma online

Business Summary: Lexicon Pharmaceuticals, Inc., is a biopharmaceutical company. The Company is engaged in research and development of drug candidates and the commercialization of the drug, INPEFA (sotagliflozin). INPEFA reduces the risk of cardiovascular death, hospitalization for heart failure, and urgent heart failure visit in adults with heart failure or type 2 diabetes, chronic kidney disease (CKD), and other cardiovascular risk factors. Sotagliflozin is an orally delivered small molecule drug candidate as a treatment for hypertrophic cardiomyopathy (HCM) and conducts the SONATA-HCM pivotal Phase 3 clinical trial of sotagliflozin in that indication. The Company develops pilavapadin, an orally delivered small molecule drug candidate, as a treatment for neuropathic pain. The Company also develops LX9851, an orally delivered small molecule drug candidate, for the treatment of obesity and associated cardiometabolic disorders.
Financial Summary: BRIEF: For the fiscal year ended 31 December 2025, Lexicon Pharmaceuticals Inc revenues increased 60% to $49.8M. Net loss decreased 75% to $50.3M. Revenues reflect Licensing revenue increase of 80% to $45M, Royalties and other revenue increase of 95% to $156K. Lower net loss reflects Discovery, Devlopment & commercialization segment loss decrease of 75% to $48.9M.